LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Celastrol | 3.33 | uM | LJP6 | 1 | G08 | 72 | hr | 2543 | 1546 | 5578 | 0.2771 | -0.3286 |
| SK-BR-3 | Celastrol | 3.33 | uM | LJP6 | 2 | G08 | 72 | hr | 2543 | 1472 | 5578 | 0.2639 | -0.3530 |
| SK-BR-3 | Celastrol | 3.33 | uM | LJP6 | 3 | G08 | 72 | hr | 2543 | 1525 | 5578 | 0.2734 | -0.3356 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP5 | 1 | F02 | 72 | hr | 2543 | 1051 | 5578 | 0.1884 | -0.4917 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP5 | 2 | F02 | 72 | hr | 2543 | 1103 | 5578 | 0.1977 | -0.4746 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP5 | 3 | F02 | 72 | hr | 2543 | 1267 | 5578 | 0.2271 | -0.4206 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP6 | 1 | G02 | 72 | hr | 2543 | 1007 | 5578 | 0.1805 | -0.5062 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP6 | 2 | G02 | 72 | hr | 2543 | 1050 | 5578 | 0.1882 | -0.4920 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP6 | 3 | G02 | 72 | hr | 2543 | 1117 | 5578 | 0.2002 | -0.4700 |
| SK-BR-3 | CHIR-99021 | 3.33 | uM | LJP6 | 1 | P14 | 72 | hr | 2543 | 3581 | 5578 | 0.6419 | 0.3418 |
| SK-BR-3 | CHIR-99021 | 3.33 | uM | LJP6 | 2 | P14 | 72 | hr | 2543 | 4774 | 5578 | 0.8558 | 0.7349 |
| SK-BR-3 | CHIR-99021 | 3.33 | uM | LJP6 | 3 | P14 | 72 | hr | 2543 | 4861 | 5578 | 0.8714 | 0.7636 |
| SK-BR-3 | CP724714 | 3.33 | uM | LJP5 | 1 | A08 | 72 | hr | 2543 | 2485 | 5578 | 0.4455 | -0.0193 |
| SK-BR-3 | CP724714 | 3.33 | uM | LJP5 | 2 | A08 | 72 | hr | 2543 | 2409 | 5578 | 0.4318 | -0.0443 |
| SK-BR-3 | CP724714 | 3.33 | uM | LJP5 | 3 | A08 | 72 | hr | 2543 | 2585 | 5578 | 0.4634 | 0.0137 |
| SK-BR-3 | CP466722 | 3.33 | uM | LJP5 | 1 | I08 | 72 | hr | 2543 | 5835 | 5578 | 1.0459 | 1.0845 |
| SK-BR-3 | CP466722 | 3.33 | uM | LJP5 | 2 | I08 | 72 | hr | 2543 | 6299 | 5578 | 1.1291 | 1.2373 |
| SK-BR-3 | CP466722 | 3.33 | uM | LJP5 | 3 | I08 | 72 | hr | 2543 | 5803 | 5578 | 1.0402 | 1.0739 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 1 | A20 | 72 | hr | 2543 | 4002 | 5578 | 0.7174 | 0.4805 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 2 | A20 | 72 | hr | 2543 | 3691 | 5578 | 0.6616 | 0.3781 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 3 | A20 | 72 | hr | 2543 | 4014 | 5578 | 0.7195 | 0.4845 |
| SK-BR-3 | Momelotinib | 3.33 | uM | LJP5 | 1 | P08 | 72 | hr | 2543 | 4174 | 5578 | 0.7482 | 0.5372 |
| SK-BR-3 | Momelotinib | 3.33 | uM | LJP5 | 2 | P08 | 72 | hr | 2543 | 4460 | 5578 | 0.7995 | 0.6314 |
| SK-BR-3 | Momelotinib | 3.33 | uM | LJP5 | 3 | P08 | 72 | hr | 2543 | 4385 | 5578 | 0.7860 | 0.6067 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP5 | 1 | D02 | 72 | hr | 2543 | 4250 | 5578 | 0.7618 | 0.5623 |